Research & Innovation - Participant Portal

Search

TOPIC : Demonstration pilots for implementation of personalised medicine in healthcare

Topic identifier: SC1-BHC-25-2019
Publication date: 27 October 2017

Types of action: IA Innovation action
DeadlineModel:
Planned opening date:
two-stage
26 July 2018
Deadline:
2nd stage Deadline:
02 October 2018 17:00:00
16 April 2019 17:00:00

Time Zone : (Brussels time)
  Horizon 2020 H2020 website
Pillar: Societal Challenges
Work Programme Year: H2020-2018-2020
Topic Description
Specific Challenge:

Personalised medicine (PM) has the potential to respond to, among others, the increasing burden of co-morbidities and thus enhance the sustainability of healthcare systems. With the increasing number of scientific approaches available, it is crucial to demonstrate the benefit of large scale deployment of personalised medicine to citizens and healthcare systems. This was also one of the conclusions of the Personalised Medicine Conference 2016 (http://ec.europa.eu/research/conferences/2016/permed2016/index.cfm).

Scope:

The pilot projects should demonstrate the benefit for individuals as well as the implementability and economic viability of personalised medicine approaches in real life healthcare settings. The pilots should be tailored to the needs of citizens, making use of a wide variety of data and proposing prediction, prevention or treatment solutions, focussing on diseases with high burden to society (taking due account of sex/gender differences) and including multi-morbidity conditions if relevant. The use of big data approaches and high performance computing is encouraged. Applicants should ensure coordination with national, regional or local authorities engaging in healthcare environments and should aim at linking different institutions (hospitals, other healthcare facilities, public health authorities, payers etc.). The pilot projects should engage partners in regions or cities having adopted or that are in advanced planning for introducing PM approaches. Patient representatives as well as partners from countries that are in the process of upgrading their healthcare systems should be involved, ensuring a wide European dimension. Applicants should address the health economic, ethical, legal and societal aspects of the proposed action. Taking into account the advances already achieved for PM approaches in cancer and rare diseases, projects with primary focus on these diseases are excluded from the scope of this topic.

The Commission considers that proposals requesting a contribution from the EU of between EUR 18 and EUR 20 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:
  • Evidence for a PM-based model of care that can be used as a basis for the delivery of new ways of care organisation.
  • Demonstration of the viability and feasibility of PM approaches in real-life settings and at a large scale, exemplifying potential for savings in overall healthcare costs.
  • Widening of PM approaches to include diseases other than cancer and rare diseases.
  • Linking of different actors for healthcare, economy, lifestyle, healthy living and regulation, making use of the multitude of data available.
Cross-cutting Priorities:

Socio-economic science and humanities
Gender
Open Innovation

Topic conditions and documents

1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.

2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.

Taking into account the advances already achieved for Personalised Medicine approaches in cancer and rare diseases, projects with primary focus on these diseases are excluded from the scope of this topic.

Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.

The thresholds for each criterion in the second stage of a two-stage process will be 4, 4 and 3. The cumulative threshold will be 12.

3. Evaluation:

  • Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
  • Submission and evaluation processes are described in the Online Manual.

4. Indicative time for evaluation and grant agreements:

Information on the outcome of evaluation (two-stage call):

For stage 1: maximum 3 months from the deadline for submission.
For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.

5. Proposal templates, evaluation forms and model grant agreements (MGA):

Innovation Action:

Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement

Essential information for clinical studies

6. Additional provisions:

Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.

Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.

7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.

Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.

Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.

Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.

Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.

Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.

Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.

The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.

8. Additional documents:

Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020

Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme

Submission Service

The submission system is planned to be opened on the date stated on the topic header.

Get support

H2020 Online Manual is your guide on the procedures from proposal submission to managing your grant.

Participant Portal FAQ – Submission of proposals.

National Contact Points (NCP) - contact your NCP for further assistance in your national language(s).

Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.

Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.

IT Helpdesk - contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.

Ethics – for compliance with ethical issues, see the Online Manual and Science and Society Portal

European IPR Helpdesk assists you on intellectual property issues

CEN and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at research@cencenelec.eu

The European Charter for Researchers and the Code of Conduct for their recruitment

Partner Search Services help you find a partner organisation for your proposal.